The Use Of Nicotinic Acid In The Treatment Of Heart Disease – Part 2 of 3
They received either 2 grams of extended-release niacin addition 40 milligrams of laropiprant or matching placebos. All of the patients also took Zocor (simvastatin). The patients from China, the United Kingdom and Scandinavia were followed for an usual of almost four years.
Besides showing no helpful effect on heart health outcomes, the team noted that people taking niacin had about the same amount of heart-related events (13,2 percent) as those who took a placebo as an alternative (13,7 percent). Side effects were common. As already reported online Feb 26, 2013 in the European Heart Journal, by the end of the study, 25 percent of patients taking niacin together with laropiprant had stopped their treatment, compared with 17 percent of the patients taking a placebo.
And “The main reason for patients stopping the healing was because of adverse side effects, such as itching, rashes, flushing, indigestion, diarrhea, diabetes and muscle problems,” Armitage said at the time in a journal news release. “We found that patients allocated to the experiential treatment were four times more likely to stop for skin-related reasons, and twice as likely to stop because of gastrointestinal problems or diabetes-related problems”. Patients taking niacin and laropiprant had a more than fourfold increased gamble of muscle pain or weakness compared to the placebo group, the team noted.